Sugi Predict

Sugi Predict / Compounds / SCHEMBL6493261

SCHEMBL6493261

SCHEMBL6493261

COC(=O)c1ccc2nc(C)n(Cc3ccc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)cc3Cl)c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ PPARG P37231 2/20 0.34
▸ TP53 P04637 2/20 0.33
▸ NQO2 P16083 1/20 0.32
▸ BRD4 O60885 1/20 0.31
▸ TLR7 Q9NYK1 1/20 0.31
▸ HDAC3 O15379 1/20 0.31
▸ HDAC4 P56524 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC7 Q8WUI4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491418 0.92 MAPT (0.37) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6502447 0.91 MAPT (0.38) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6493788 0.86 ALDH1A1 (0.37) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6301183 0.86 NQO2 (0.42) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6502592 0.85 CDK9 (0.33) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6503682 0.83 ALDH1A1 (0.43) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6503105 0.83 ALDH1A1 (0.38) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6491577 0.83 ALDH1A1 (0.39) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6305523 0.82 MAPT (0.41) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6300374 0.82 PPARG (0.47) MAPTALDH1A1SMN1; SMN2HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 — — US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 — — US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 — — US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A MAPT 4144/4885ALDH1A1 476/4885SMN1; SMN2 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.